DOJ Updated Emergency Scheduling for Opioid Substances
Federal regulators have set new potency thresholds for specific kratom-related compounds to improve oversight.
Updated on Oct. 10, 2026 in Substance Abuse
Live Poll
Should the government regulate botanical products containing trace amounts of synthetic opioid substances?
The Department of Justice and the DEA have issued updated emergency scheduling actions for 7-hydroxymitragynine, mitragynine pseudoindoxyl, MGM-15, and MGM-16. These measures establish specific concentration and ratio limits to distinguish between botanical kratom and highly concentrated opioid products.
Why it matters
These actions aim to protect communities by curbing the availability of potentially addictive opioid substances. By setting clear scientific thresholds, regulators can target concentrated products while accounting for trace amounts found in traditional botanical kratom.
Federal guidance establishes a Schedule I control threshold of 1 milligram per gram for solids or 1 milligram per milliliter for liquids, and a 100-to-1 ratio for mitragynine. These criteria serve to differentiate between intentional product concentration and natural trace occurrence.
The players
Department of Justice
The federal executive department responsible for the enforcement of laws and the administration of justice in the United States.
Drug Enforcement Administration
The federal agency tasked with combating drug smuggling and use within the United States, including managing controlled substance scheduling.
HHS
The Department of Health and Human Services provides the scientific and medical recommendations that inform federal drug scheduling decisions.
The details
The DEA distinguishes between natural botanical kratom and intentionally enhanced products that contain concentrated opioids. Substances exceeding the established 1 milligram per gram or 1 milligram per milliliter thresholds, or those failing the 100-to-1 ratio, face tighter regulation to prevent the distribution of potent, addictive substances.
Timeline
August 26, 2026: The DEA temporarily placed MGPI, MGM-15, and MGM-16 into Schedule I.
October 9, 2026: The Department of Justice announced updated emergency scheduling actions.
The temporary scheduling controls remain in effect throughout the current 30-day Notice of Intent period.
Health Landscape
This action follows the legal framework established by the Controlled Substances Act to regulate emerging substances. It reflects a shift toward using precise scientific concentration thresholds to address the distinction between botanical materials and chemically enhanced products.
If you use products containing kratom or related botanical extracts, consult your physician about the potential for unintended opioid exposure. These regulatory updates emphasize the importance of verifying the source and purity of supplements with a healthcare provider.
The takeaway
Regulators are increasingly targeting concentrated opioid-like additives to differentiate them from traditional botanical kratom. Readers should discuss any concerns about supplement potency with their doctor and prioritize products from transparent, regulated sources.
Further reading
For more information on current federal regulations, visit the Substance Abuse section.
Live Poll
Should the government regulate botanical products containing trace amounts of synthetic opioid substances?
